In our evaluation of safingol in the cisplatin resistant cell line AGSCIS4 and the gastric cancer cell line N87 we used safingol at concentrations ranging from 0.375–12 μM, which is well within the readily achievable serum plasma concentrations of safingol in cancer patients and at which significant decreases in serum S1P are reported [38]. This evidence concerns the gene MBTPS1 and gastric cancer.